In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deals In Depth: September 2017

Executive Summary

Halozyme will use its Enhanze technology to improve the delivery of BMS's immuno-oncology drugs in a new $1.9 billion deal; for $725 million up front and $375 million in earn-outs, Teleflex expanded its urology device portfolio with the NeoTract buy. Device financing surged due to CooperSurgical's $1.1 billion bridge loan, which is helping to support the acquisition of Teva's Paragard IUD.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts